Send the link below via email or IMCopy
Present to your audienceStart remote presentation
- Invited audience members will follow you as you navigate and present
- People invited to a presentation do not need a Prezi account
- This link expires 10 minutes after you close the presentation
- A maximum of 30 users can follow your presentation
- Learn more about this feature in our knowledge base article
Transcript of Ebola Presentation
Education is the most powerful weapon which you can use to change the world.
Mapp Biopharmaceutical makes Ebola Drug for U.S.
Monday, September 15, 2014
Vol XCIII, No. 311
Sub Saharan Times
Ebola is back!
World Health Organization
Film industry is dying
There is a desperate need
Fujifilm "needs to prosper in a world of abrupt changes and discontinuities"
Envision new Strategies
Develop new plans
Change the way of doing business
Shipping treatment to Ebola hit areas
Too few quantities
Not tested on people or animals infected with Ebola
Not sure the possible treatment will work
Fujifilm: Trying for a Cure
What is Ebola?
How is it contracted?
When did it come back?
Where is it thought to go?
Who will Ebola affect?
Why should we help Africa?
Background of Ebola . . .
Declared an international health risk
WHO met with the Presidents of Guinea, Liberia, Sierra Leone and Cote D’Ivoire in Conakry, the Guinean capital, on Friday to launch a new joint $100 million response plan intended to mark “a turning point” of an intensified international, regional and national campaign to bring the outbreak under control.
Appropriate education and training on infection prevention and control.
Has issued to conduct exit screening at international airports, seaports, and major land crossing.
The U.S. Department of Health and Human Services' Office of the Assistant Secretary for Preparedness & Response contracted Mapp Biopharmaceutical to develop an Ebola drug.
The ASPR's Biomedical Advance Research Development Authority (BARDA) will provide the funding of $24.9 million.
UNICEF and the UN
Shipping protective equipment and essential medicine to affected areas.
2014 Ebola Outbreak Distribution Map
Developing drugs and vaccines to protect against Ebola as a biological threat has been a long-term goal of the United States government.
The West and Central African Regional Office and the West African Health Organization alongside the UNICEF are committed to efficient and coordinated intervention of populations.
Pledged up to 200 million in emergency funding to help fight the spread of Ebola.
U.S. Center of Disease Control & Prevention
Deployed several teams of public health experts to the West African region to expand response activities with partners.
ZMapp, is a combination of three monoclonal antibodies. These Monoclonal antibodies bind certain virus proteins and neutralize the virus, decreasing the amount of the virus the patient's immune system has to fight.
Populations at risk for an epidemic
Zmapp represents opportunity and a challenge for Mapp Biopharmaceutical and the U.S.
WHO has established an Ebola response center in Conakry, Guinea.